Heslop HE - Search Results

1

T-cell therapy in the treatment of post-transplant lymphoproliferative disease.

Bollard CM, Rooney CM, Heslop HE. Bollard CM, et al. Among authors: heslop he. Nat Rev Clin Oncol. 2012 Sep;9(9):510-9. doi: 10.1038/nrclinonc.2012.111. Epub 2012 Jul 17. Nat Rev Clin Oncol. 2012. PMID: 22801669 Free PMC article. Review.

2

Gene transfer and bone marrow transplantation.

Brenner MK, Heslop HE, Rill D, Li C, Nilson T, Roberts M, Smith C, Krance R, Rooney C. Brenner MK, et al. Among authors: heslop he. Cold Spring Harb Symp Quant Biol. 1994;59:691-7. doi: 10.1101/sqb.1994.059.01.080. Cold Spring Harb Symp Quant Biol. 1994. PMID: 7587132 No abstract available.

3

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.

Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM. Smith CA, et al. Among authors: heslop he. J Hematother. 1995 Apr;4(2):73-9. doi: 10.1089/scd.1.1995.4.73. J Hematother. 1995. PMID: 7633844

4

Gene marking after bone marrow transplantation.

Brenner MK, Rill DR, Heslop HE, Rooney CM, Roberts WM, Li C, Nilson T, Krance RA. Brenner MK, et al. Among authors: heslop he. Eur J Cancer. 1994;30A(8):1171-6. doi: 10.1016/0959-8049(94)90478-2. Eur J Cancer. 1994. PMID: 7654451 Review. No abstract available.

5

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Rooney CM, et al. Among authors: heslop he. Lancet. 1995 Jan 7;345(8941):9-13. doi: 10.1016/s0140-6736(95)91150-2. Lancet. 1995. PMID: 7799740

6

Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease.

Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Rooney CM, et al. Among authors: heslop he. Br J Haematol. 1995 Jan;89(1):98-103. doi: 10.1111/j.1365-2141.1995.tb08904.x. Br J Haematol. 1995. PMID: 7833284

7

Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.

Heslop HE, Brenner MK, Rooney C, Krance RA, Roberts WM, Rochester R, Smith CA, Turner V, Sixbey J, Moen R, et al. Heslop HE, et al. Hum Gene Ther. 1994 Mar;5(3):381-97. doi: 10.1089/hum.1994.5.3-381. Hum Gene Ther. 1994. PMID: 8018749 Clinical Trial. No abstract available.

8

Donor T cells to treat EBV-associated lymphoma.

Heslop HE, Brenner MK, Rooney CM. Heslop HE, et al. N Engl J Med. 1994 Sep 8;331(10):679-80. doi: 10.1056/NEJM199409083311017. N Engl J Med. 1994. PMID: 8052285 No abstract available.

9

Correction of Duncan's syndrome by allogeneic bone marrow transplantation.

Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE. Williams LL, et al. Among authors: heslop he. Lancet. 1993 Sep 4;342(8871):587-8. doi: 10.1016/0140-6736(93)91413-g. Lancet. 1993. PMID: 8102723

10

Epstein-Barr infection after bone marrow transplantation.

Heslop HE, Li C, Krance RA, Loftin SK, Rooney CM. Heslop HE, et al. Blood. 1994 Mar 15;83(6):1706-8. Blood. 1994. PMID: 8123864 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

424 results

Search Page

Filters